Publications
Search our bibliography using the filters on the right-hand side.
Displaying 101 through 150 of 199 publications.
Skip to main content
Cronin-Fenton DP, Kjaersgaard A, Norgaard M, Pedersen IS, Thomassen M, Kaye JA, Gutierrez L, Telford C, Lewis J, Tyczynski JE, Sorensen HT. Clinical outcomes of female breast cancer according to BRCA mutation status. Cancer Epidemiol Biomarkers Prev. 2017 Aug;49:128-37. doi: 10.1016/j.canep.2017.05.016
Iribarren C, Rahmaoui A, Long AA, Szefler SJ, Bradley MS, Carrigan G, Eisner MD, Chen H, Omachi TA, Farkouh ME, Rothman KJ. Cardiovascular and cerebrovascular events among patients receiving omalizumab: results from EXCELS, a prospective cohort study of moderate-to-severe asthma. J Allergy Clin Immunol. 2017 May;139(5):1489-1495. doi: 10.1016/j.jaci.2016.07.038.
Iribarren C, Rothman KJ, Bradley MS, Carrigan G, Eisner MD, Chen H. Cardiovascular and cerebrovascular events among patients receiving omalizumab: pooled analysis of patient-level data from 25 randomized, double-blind, placebo-controlled clinical trials. J Allergy Clin Immunol. 2017 May;139(5):1678-80. doi: 10.1016/j.jaci.2016.12.953
Herring W, Rosen B. Early economic model for respiratory syncytial virus vaccination in older adults. Presented at the 2017 Respiratory Syncytial Virus Consortium in Europe; May 2017. Antwerp, Belgium.
Glaser DA, Hebert AA, Fehnel S, DiBenedetti D, Nelson L, Drew J, Pariser DM. The axillary sweating daily diary: a validated patient-reported outcome measure to assess axillary hyperhidrosis symptom severity. Poster presented at the 2017 Maui Derm for Dermatologists; March 2017. Maui, HI.
Hutchinson AB, Hicks KA, Yaylali E, Tucker E, Jacobson E, Sansom SL. Cost-effectiveness of HIV screening of heterosexuals in the United States. Poster presented at the 2017 Conference on Retroviruses and Opportunistic Infections (CROI); February 14, 2017. Seattle, WA.
O'Leary A, DiNenno E, Honeycutt A, Allaire B, Neuwahl S, Hicks K, Sansom S. Contribution of anal sex to HIV prevalence among heterosexuals: a modeling analysis. AIDS Behav. 2017 Jan 5. doi: 10.1007/s10461-016-1635-z
Yaylali E, Farnham P, Sansom S, Hicks KA, Honeycutt A, Tucker E. Using the HOPE model for evaluating HIV interventions in the US. Presented at the 2016 INFORMS Annual Meeting; November 13, 2016. Nashville, TN.
Jacobson E, Hicks KA, Yaylali E, Chen YH, Sansom S. Effects of reaching national HIV/AIDS strategy viral load suppression goal on HIV incidence, by race and ethnicity, in the United States. Presented at the 38th Annual North American Meeting of the Society for Medical Decision Making; October 24, 2016. Vancouver, Canada.
Chertow GM, Liu J, Monda KL, Gilbertson DT, Brookhart MA, Beaubrun AC, Winkelmayer WC, Pollock A, Herzog CA, Ashfaq A, Sturmer T, Rothman KJ, Bradbury BD, Collins AJ. Epoetin alfa and outcomes in dialysis amid regulatory and payment reform. J Am Soc Nephrol. 2016 Oct;27(10):3129-38. doi: 10.1681/ASN.2015111232
Graham J, McBride D, Stull D, Halliday A, Alexopoulos ST, Balp MM, Griffiths M, Agirrezabal I, Zuberbier T, Brennan A. Cost utility of omalizumab compared with standard of care for the treatment of chronic spontaneous urticaria. Pharmacoeconomics. 2016 Aug;34(8):815-27. doi: 10.1007/s40273-016-0412-1
Clark M, DiBenedetti D, Perez V. Cognitive dysfunction and work productivity in major depressive disorder. Expert Rev Pharmacoecon Outcomes Res. 2016 Jun 8. doi: 10.1080/14737167.2016.1195688
Stenehjem DD, Tyczynski J, Unni SK, Bauer H, Sainski A, Deka R, Schauerhamer M, Tak C, Ma J, Gutierrez L, Kaye JA, Telford C, Brixner DI, Biskupiak JE. Increasing BRCA testing in breast cancer patients at a NCI designated Comprehensive Cancer Center. Poster presented at the Sixth International Symposium on Hereditary Breast and Ovarian Cancer; May 2016. Montreal, Canada.
Stenehjem DD, Telford C, Unni SK, Bauer H, Sainski A, Deka R, Schauerhamer M, Ye X, Tak C, Ma J, Gutierrez L, Kaye JA, Tyczynski J, Brixner DI, Biskupiak JE. Utilization of neoadjuvant chemotherapy in women with breast cancer tested for BRCA mutations at a NCI designated Comprehensive Cancer Center. Poster presented at the Sixth International Symposium on Hereditary Breast and Ovarian Cancer; May 2016. Montreal, Canada.
Korman N, Sofen H, Rich P, Fretzin S, Zhao Y, Herrera V, Mordin M, Williams N, Nyirady J, Tyring S. Secukinumab provides more effective relief from psoriasis impact on personal relationships and influence on clothes worn than etanercept and placebo. Poster presented at the American Academy of Dermatology 74th Annual Meeting; March 4, 2016. Washington, DC. [abstract] J Am Acad Dermatol. 2016 May; 74(5 (Supplement 1)):AB272. doi: 10.1016/j.jaad.2016.02.1049
Tyring S, Sofen H, Fretzin S, Rich P, Zhao Y, Herrera V, Sherif B, Williams N, Nyirady J, Korman N. Secukinumab provides more effective relief from skin-related quality-of-life impact than etanercept in moderate to severe psoriasis. Poster presented at the American Academy of Dermatology 74th Annual Meeting; March 4, 2016. Washington, DC. [abstract] J Am Acad Dermatol. 2016 May; 74(5 (Supplement 1)):AB272. doi: 10.1016/j.jaad.2016.02.1050
Sofen H, Korman N, Rich P, Fretzin S, Zhao Y, Herrera V, Sherif B, McLeod L, Nyirady J, Tyring S. Secukinumab provides more effective relief from skin-related quality-of-life impact than placebo in moderate to severe psoriasis. Poster presented at the American Academy of Dermatology 74th Annual Meeting; March 4, 2016. Washington, DC. [abstract] J Am Acad Dermatol. 2016 May; 74(5 (Supplement 1)):AB272. doi: 10.1016/j.jaad.2016.02.1051
Strober B, Sigurgeirsson B, Popp G, Sinclair R, Krell J, Stonkus S, Septe M, Elewski BE, Gottlieb AB, Zhao Y, Tran MH, Karpov A, McLeod LD, Mordin M, Papavassils C, Nyirady J, Lebwohl M. Secukinumab improves patient-reported psoriasis symptoms of itching, pain, and scaling: results of two phase 3, randomized, placebo-controlled clinical trials. Int J Dermatol. 2016 Apr;55(4):401-7. doi: 10.1111/ijd.13236
Gilbertson DT, Bradbury BD, Wetmore JB, Weinhandl ED, Monda KL, Liu J, Brookhart MA, Gustafson SK, Roberts T, Collins AJ, Rothman KJ. Controlling confounding of treatment effects in administrative data in the presence of time-varying baseline confounders. Pharmacoepidemiol Drug Saf. 2016 Mar;25(3):269-77. doi: 10.1002/pds.3922
Yaylali E, Farnham P, Jacobson E, Allaire BT, Wagner DL, Hicks KA, Honeycutt AA, Sansom SL. Impact of improving HIV care and treatment and initiating PrEP in the US, 2015-2020. Poster presented at the 2016 Conference on Retroviruses and Opportunistic Infections (CROI); February 24, 2016. Boston, MA.
Lebwohl M, Gottlieb A, Elewski B, Rich P, Jazayeri S, Reich K, Nyirady J, Zhao Y, Tran MH, McLeod L, Mordin M, Nelson L, Strober B. Secukinumab impact on patient-reported psoriasis experiences: analysis of the psoriasis symptom diary from the ERASURE and FIXTURE trials. Poster presented at the SDPA 13th Annual Fall Dermatology Conference 2015; November 12, 2015. Orlando, FL. Previously presented at the 73rd Annual Meeting of the American Academy of Dermatology.
McLeod L, Mallya AG, Fox T, Zhao Y, Mordin M, Strober B. Psoriasis patients with PASI90 response achieve greater health-related quality of life improvements than those with PASI75 response. Poster presented at the 16th Annual Las Vegas Dermatology Seminar; November 5, 2015. Las Vegas, NV. Previously presented at the 23rd European Academy of Dermatology and Venereology Congress.
Lebwohl M, Gottlieb A, Elewski B, Rich P, Jazayeri S, Reich K, Nyirady J, Zhao Y, Tran MH, McLeod L, Mordin M, Nelson L, Strober B. Secukinumab impact on patient-reported psoriasis experiences: analysis of the psoriasis symptom diary from the ERASURE and FIXTURE trials. Poster presented at the 16th Annual Las Vegas Dermatology Seminar; November 5, 2015. Las Vegas, NV. Previously presented at the 73rd Annual Meeting of the American Academy of Dermatology.
Yaylali E, Farnham PG, Hicks KA, Honeycutt A, Sansom SL, Tucker EL. Developing a dynamic compartmental model of HIV in the United States. Poster presented at the INFORMS Annual Meeting; November 3, 2015. Philadelphia, PA.
McLeod L, Mallya UG, Fox T, Zhao Y, Mordin M, Strober B. Psoriasis patients with PASI90 response achieve greater health-related quality of life improvements than those with PASI75 response. Poster presented at the SDPA 13th Annual Fall Dermatology Conference 2015; November 2015. Orlando, FL. Previously presented at the 23rd European Academy of Dermatology and Venereology Congress.
Graham J, McBride D, Stull D, Halliday A, Alexopoulos ST, Balp M, Griffiths M, Agirrezabal I, Brennan A. Cost-utility of omalizumab compared with standard of care for the treatment of chronic spontaneous urticaria (CSU). Poster presented at the 2015 ISPOR 18th Annual European Congress; November 2015. Milan, Italy.
Kimball AB, Schenfeld J, Accortt NA, Anthony MS, Rothman KJ, Pariser D. Cohort study of malignancies and hospitalised infectious events in treated and untreated patients with psoriasis and a general population in the United States. Br J Dermatol. 2015 Nov;173(5):1183-90. doi: 10.1111/bjd.14068
Stein D, Weatherall M, Garratt C, Aantaa R, Conti G, Lewis MA, Moore N, Gutthann S. Methodological considerations for the implementation of a European mandated retrospective drug utilisation study (DUS) to investigate the use of dexmedetomidine (DEXDOR®) in clinical practice. Poster presented at the 2015 ISPOR 18th Annual European Congress; November 2015. Milan, Italy.
White MV, Silvia S, Hollis KA, Wooddell M, Hogue SL. Characteristics and treatment of anaphylactic events in a US school setting: results from the EPIPEN4SCHOOLS® program survey. Poster presented at the American Academy of Pediatrics 2015; October 24, 2015. Washington, DC. Previously presented at the 2015 AAAAI Annual Meeting.
Chen YH, Yaylali E, Hicks KA, Tucker EL, Farnham PG, Sansom SL. Calibrating dynamic compartmental models of human immunodeficiency virus in the United States. Poster presented at the Society for Medical Decision Making (SMDM) 37th Annual North American Meeting; October 18, 2015. St. Louis, MO.
McLeod L, Mallya UG, Fox T, Zhao Y, Mordin M, Strober B. Psoriasis patients with PASI90 response achieve greater health-related quality of life improvements than those with PASI75 response. Poster presented at the Fall Clinical Dermatology Conference; October 2015. Las Vegas, NV. Previously presented at the 23rd European Academy of Dermatology and Venereology Congress.
Lebwohl M, Gottlieb A, Elewski B, Rich P, Jazayeri S, Reich K, Nyirady J, Zhao Y, Tran MH, McLeod L, Mordin M, Nelson L, Strober B. Secukinumab impact on patient-reported psoriasis experiences: analysis of the psoriasis symptom diary from the erasure and fixture trials. Poster presented at the Fall Clinical Dermatology Conference; October 2015. Las Vegas, NV. Previously presented at the 73rd Annual Meeting of the American Academy of Dermatology.
Garratt C, Weatherall M, Pohjanjousi P, Aantao R, Conti G, Lewis M, Moore N, Perez-Gutthann S. A multinational, drug utilisation study to investigate the use of dexmedetomidine (DEXDOR®) in clinical practice in the EU. Poster presented at the 2015 ESICM's 28th Annual Congress; October 3, 2015. Berlin, Germany. [abstract] Intensive Care Med Exp. 2015 Oct 1; 3(Suppl 1):A322. Previously presented at the 31st ICPE International Conference on Pharmacoepidemiology and Therapeutic Risk Management. doi: 10.1186/2197-425X-3-S1-A322
Gottlieb A, Strober B, Lebwohl M, Kaufmann R, Pariser D, Narbutas R, Nyirady J, Zhao Y, Tran MH, McLeod L, Odom D, Elewski B. Secukinumab in psoriasis: relationship between clinical- and patient-reported outcomes using clinical trial data from the erasure and fixture trials. Poster presented at the Fall Clinical Dermatology Conference; October 2015. Las Vegas, NV. Previously presented at the 73rd Annual Meeting of the American Academy of Dermatology.
McLeod L, Mallya UG, Fox T, Zhao Y, Mordin M, Strober B. Psoriasis patients with PASI90 response achieve greater health-related quality of life improvements than those with PASI75 response. Poster presented at the 2nd Annual Maui Derm NP+PA Fall 2015 Meeting; September 2015. Washington, DC. Previously presented at the 23rd European Academy of Dermatology and Venereology Congress.
Perez-Gutthann S, Weatherall M, Garratt C, Pohjanjousi P, Aantaa R, Conti G, Lewis M, Moore N. A multinational, drug utilisation study to investigate the use of dexmedetomidine (Dexdor®) in clinical practice in the EU. Poster presented at the 31st ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 2015. Boston, MA. [abstract] Pharmacoepidemiol Drug Saf. 2015 Sep; 24(S1):95-6. doi: 10.1002/pds.3838
Lebwohl M, Gottlieb A, Elewski B, Rich P, Jazayeri S, Reich K, Nyirady J, Zhao Y, Tran MH, McLeod L, Mordin M, Nelson L, Strober B. Secukinumab impact on patient-reported psoriasis experiences: analysis of the psoriasis symptom diary from the erasure and fixture trials. Poster presented at the 2nd Annual Maui Derm NP+PA Fall 2015 Meeting; September 2015. Washington, DC. Previously presented at the 73rd Annual Meeting of the American Academy of Dermatology.
Gottlieb A, Strober B, Lebwohl M, Kaufmann R, Pariser D, Narbutas R, Nyirady J, Zhao Y, Tran MH, McLeod L, Odom D, Elewski B. Secukinumab in psoriasis: relationship between clinical- and patient-reported outcomes using clinical trial data from the erasure and fixture trials. Poster presented at the 2nd Annual Maui Derm NP+PA Fall 2015 Meeting; September 2015. Washington, DC. Previously presented at the 73rd Annual Meeting of the American Academy of Dermatology.
Johannes CB, Calingaert B, Saltus C, Kaplan S, Grubb E, Kaye JA, Andrews EB. Description of antiparkinsonian drug use in US Medicare claims database: a feasibility assessment. Poster presented at the 31st ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 2015. Boston, MA. [abstract] Pharmacoepidemiol Drug Saf. 2015 Aug; 24(S1):85-6.
White MV, Hogue SL, Bennett ME, Goss D, Millar K, Hollis K, Siegel PH, Wolf RA, Wooddell M, Silvia S. EpiPen4Schools pilot survey: occurrence of anaphylaxis, triggers, and epinephrine administration in a U.S. school setting. Allergy Asthma Proc. 2015 Jul;36(4):306-12. doi: 10.2500/aap.2015.36.3859
Bonthapally V, Ma E, Viviani S, Radford J, Brice P, von Tresckow B, Thomas E, Teasell J, Gnanasakthy A, Odom DM. Healthcare utilization in the AETHERA trial: phase 3 Study of brentuximab vedotin in patients at increased risk of residual hodgkin lymphoma post-ASCT. Poster presented at the 13th International Conference on Malignant Lymphoma (ICML); June 17, 2015. Lugano, Switzerland.
McLeod LD, Mallya UG, Fox T, Zhao Y, Mordin MM, Strober B. Psoriasis patients with PASI90 response achieve greater health-related quality of life improvements than those with PASI75 response. Poster presented at the SDPA Annual Summer Dermatology Conference 2015; June 4, 2015. Las Vegas, NV. Previously presented at the 23rd European Academy of Dermatology and Venereology Congress.
Bonthapally V, Ma E, Viviani S, Radford J, Brice P, von Tresckow B, Thomas E, Teasell J, Gnanasakthy A, Odom DM, Zhu Y, Lee S, Carlson P, Huebner D, Sweetenham J, Moskowitz C, Walewski J. Brentuximab vedotin in patients at increased risk of hodgkin lymphoma progression post autologous stem cell transplant: evaluation of healthcare resource utilization in the AETHERA trial. Poster presented at the 20th Congress of the European Hematology Association; June 2015. Vienna, Austria.
Stenehjem DD, Tyczynski JE, Unni SK, Bauer H, Sainski A, Deka R, Shauehamer M, Gutierrez LP, Kaye JA, Telford C, Brixner DI, Biskupiak DI. Evaluation of BRCA mutation (BRCAm) testing patterns, clinical characteristics and overall survival (OS) in breast cancer (BC) patients over a 20-year period. J Clin Oncol. 2015 May 29;33(15_suppl):e12518. doi: 10.1200/jco.2015.33.15_suppl.e12518
Tennis P, Chan KA, Curkendall SN, Li DK, Mines D, Peterson C, Andrews EB, Calingaert B, Chen HY, Deshpande G, Everage N, Holick CN, Meyer NM, Nkhoma ET, Quinn S, Rothman KJ, Esposito DB. Topiramate use during pregnancy and major congenital malformations in multiple populations. Birth Defects Res Part A Clin Mol Teratol. 2015 Apr;103(4):269-75. doi: 10.1002/bdra.23357.
Gottlieb AB, Strober B, Lebwohl M, Kaufmann R, Pariser D, Narbutas R, Nyirady J, Zhao Y, Tran MH, McLeod L, Odom D, Elewski B. Secukinumab in psoriasis: relationship between clinical- and patient-reported outcomes using clinical trial data from the ERASURE and FIXTURE trials. Poster presented at the 73rd Annual Meeting of the American Academy of Dermatology; March 2015. San Francisco, CA.
Elewski B, Lebwohl M, Strober B, Szepietowski JC, Blauvelt A, Schlessinger J, Nyirady J, Zhao Y, Tran MH, McLeod L, Odom D, Gottlieb AB. Secukinumab in psoriasis: early improvement in patient-reported symptom diary predicts clinical response. Poster presented at the 73rd Annual Meeting of the American Academy of Dermatology; March 2015. San Francisco, CA.
Wooddell M, Goss DS, Hollis KA, Millar K, Silvia S, Siegel P, Bennett ME, Wolf RA, Hogue SL, White MV. Epinephrine administration for cases of anaphylaxis in a US school setting: results from the EpiPen4Schools survey. Poster presented at the 2015 AAAAI Annual Meeting; February 20, 2015. Houston, TX. [abstract] J Allergy Clin Immunol. 2015 Feb; 135(2):AB212.
McLeod LD, Mallya U, Fox T, Zhao Y, Mordin MM, Strober B. Psoriasis skin clearance for patients who achieved PASI 90 provides greater HRQOL improvements than those achieved PASI 75-89. Poster presented at the Maui Derm for Dermatologists 2015; January 25, 2015. Maui, HI.
McLeod LD, Mallya UG, Fox T, Zhao Y, Mordin MM, Strober B. Psoriasis patients with PASI 90 response achieve greater health-related quality of life improvements than those with PASI 75-89 response. Poster presented at the 2015 Winter Clinical Dermatology Conference; January 16, 2015. Kaanapali, HI.